Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

787 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site DeLand, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Madisonville, Kentucky, United States
  • GSK Investigational Site Columbus, Ohio, United States
View Trial Details
Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327

Conditions
Cardiovascular Diseases, Chronic Disease, Disease Attributes, +6 more
Locations
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Coeur d'Alene, Idaho, United States
  • GSK Investigational Site Charlotte, North Carolina, United States
  • GSK Investigational Site Cincinnati, Ohio, United States
View all 54 locations
View Trial Details
Completed

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Upland, California, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Saint Charles, Missouri, United States
View all 54 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01009463

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Peoria, Arizona, United States
View all 188 locations
View Trial Details
Completed

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

NCT02586493

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Ormond Beach, Florida, United States
View all 16 locations
View Trial Details
Completed

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Sunset, Louisiana, United States
  • GSK Investigational Site Easley, South Carolina, United States
  • GSK Investigational Site Spartanburg, South Carolina, United States
  • GSK Investigational Site Union, South Carolina, United States
View all 27 locations
View Trial Details
Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01957163

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Tampa, Florida, United States
  • GSK Investigational Site New Orleans, Louisiana, United States
View all 53 locations
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site Clearwater, Florida, United States
View all 59 locations
View Trial Details
Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01879410

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site DeLand, Florida, United States
View all 72 locations
View Trial Details
Completed

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Madisonville, Kentucky, United States
View all 50 locations
View Trial Details

Related conditions